海创药业：治疗代谢相关脂肪性肝炎（MASH）药物HP515临床Ⅱ期试验完成首批参与者入组

Core Viewpoint - Haichuang Pharmaceutical announced the completion of the first batch of participant enrollment for its self-developed HP515 clinical phase II trial aimed at treating Metabolic Associated Steatotic Liver Disease (MASH), previously known as Non-Alcoholic Steatohepatitis (NASH) [2] Company Summary - The clinical phase II trial for HP515 has recently completed its first batch of participant enrollment [2] - As of the announcement date, there are no similar targeted products approved for market in China [2]